国产一区二区三区视频精品-国产一区二区三区视频在线观看-国产一区二区三区四区五区-国产一区二区三区四区五区精品-国产一区二区三区无码免费-国产一区二区三区在线

美國Gilead Sciences
吉利德科學公司（Gilead Sciences, Inc.，NASDAQ: GILD）位于美國加利福尼亞州。是一家獨立的生化公司，致力于為患者提供更快更好的治療方案。該公司所開發和銷售的藥物廣泛應用在治療病菌傳染方面，包括病毒傳染、真菌感染和細菌傳染，公司還特別關注癌癥的治療。公司擁有liposomal藥物專門對付技術，該技術的利用使藥物對患者更加安全、簡單和有效。

　　吉利德于1987年成立，擁有特敏福由1996至2016年二十年的專利權。另外，美國國防部長拉姆斯菲爾德于1997至2001年間，為吉利德的董事會主席。

Advancing Therapeutics, Improving Lives
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet need. With each new discovery and experimental drug candidate, we seek to improve the care of patients suffering from life-threatening diseases.

Gilead’s primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.

Our portfolio of 12 marketed products includes a number of category firsts and market leaders, including Atripla? (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) - the first single-tablet regimen for HIV infection. The company's latest therapy, Viread? (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B, was approved in August 2008. Chronic hepatitis B, a serious liver disease caused by the hepatitis B virus, is the leading cause of liver cancer worldwide and affects an estimated two million individuals in the United States.

More Than 20 Years of Growth
Gilead was founded in 1987 in Foster City, California. In just over 20 years, Gilead has become a leading biopharmaceutical company with a rapidly expanding product portfolio, growing pipeline of investigational drugs and approximately 4,000 employees.

In 2008, Gilead’s annual revenues surpassed $5.3 billion. BusinessWeek has ranked Gilead #1 in its 2009 listing of the 50 best-performing companies, up from #2 last year.

Our Marketed Products
Following is a summary of Gilead's product portfolio. See our Products section for full prescribing information, including BOXED WARNINGS and Important Safety Information.

HIV/AIDS
Atripla? (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) is the first and only once-daily single tablet regimen for the treatment of HIV infection in adults. It is intended for use as a stand-alone therapy, or in combination with other antiretrovirals, and combines Gilead's Truvada? (emtricitabine and tenofovir disoproxil fumarate) with Sustiva? (efavirenz), manufactured by Bristol-Myers Squibb. (U.S. approval, 2006; E.U. approval, 2007.)
Emtriva? (emtricitabine) is a once-daily oral nucleoside reverse transcriptase inhibitor (NRTI) used in combination with other antiretroviral agents for the treatment of HIV infection in adults. Emtriva is also available as an oral solution for use in pediatric patients. (U.S. and E.U. approval, 2003.)
Truvada? (emtricitabine and tenofovir disoproxil fumarate) is a fixed-dose once-daily combination pill containing Viread? and Emtriva?. It is used in combination with other antiretroviral agents for the treatment of HIV infection in adults. (U.S. approval, 2004; E.U. approval, 2005.)
Viread? (tenofovir disoproxil fumarate) is a once-daily oral nucleotide reverse transcriptase inhibitor (NtRTI) for the treatment of HIV infection in adults in combination with other antiretroviral agents. (U.S. approval, 2001; E.U. approval, 2002.)
Liver Disease
Hepsera? (adefovir dipivoxil) is a once-daily, oral NtRTI for the treatment of patients with chronic hepatitis B. (U.S. approval, 2002; E.U. approval, 2003.)
Viread? (tenofovir disoproxil fumarate) is a once-daily oral NtRTI for the treatment of chronic hepatitis B infection in adults. (U.S. and EU approval, 2008.)
Cardiovascular
Letairis? (ambrisentan) is a novel endothelin receptor antagonist (ERA) indicated for the once-daily treatment of PAH (WHO Group 1) in patients with WHO Functional Class II or III symptoms to improve exercise capacity and delay clinical worsening. (U.S. approval, 2007; E.U. approval, 2008.)
Lexiscan? (regadenoson) injection is the first A2A adenosine receptor agonist approved by the FDA for use as a pharmacologic stress agent in radionuclide MPI studies. The product has been designed to target the A2A adenosine receptor, which is the adenosine receptor subtype responsible for coronary vasodilation. (U.S. approval, 2008.)
Ranexa? (ranolazine) is an extended-release tablet for the treatment of chronic angina. Ranexa may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors and angiotensin receptor blockers. (U.S. approval, 2006; U.S. expanded indication to include first-line treatment for chronic angina, 2008; E.U. approval, 2008.)
Respiratory
Tamiflu? (oseltamivir phosphate) is the first neuraminidase inhibitor tablet for the treatment and prevention of influenza A and B. Tamiflu was approved by the FDA for the treatment of influenza in October 1999 and for influenza prevention in November 2000. Tamiflu has been available in Europe since 2002. The product, which was developed by Gilead, is commercialized globally by Hoffmann-La Roche.
Other
AmBisome? (amphotericin B liposome for injection) is a treatment for life-threatening, systemic fungal infections in adults. (E.U. approval, 1990; U.S. approval, 1997.)
Macugen? (pegaptanib sodium injection) is an injection for the treatment of neovascular age-related macular degeneration (also known as "wet" AMD), an eye disease that destroys central vision in elderly patients. This product is marketed in the United States by OSI Pharmaceuticals. (U.S. approval, 2004.)
Vistide? (cidofovir injection) is an antiviral injection for the treatment of cytomegalovirus retinitis in adult patients with AIDS. (U.S. approval, 1996; E.U. approval, 1997.)
Growing Worldwide Footprint
Gilead has approximately 4,000 employees around the world. Corporate headquarters are located in Foster City, California. We also have additional operations in: